Market Place
Sourcing Support
Lundbeck acquires all outstanding shares of Longboard Pharma
04 Dec 2024 //
PRESS RELEASE
Lundbeck Initiates Phase III Trial with Amlenetug for MSA
27 Nov 2024 //
PHARMAWEB
Lundbeck slashes value of $250M Abide buyout after pain setback
24 Oct 2024 //
FIERCE BIOTECH
Denmark`s Lundbeck bets on epilepsy drug with $2.6 bln Longboard deal
15 Oct 2024 //
REUTERS
Lundbeck taps Charles River for AI-enabled neuro drug discovery
02 Oct 2024 //
FIERCE BIOTECH
Barbara Corcoran Raises Awareness For Alzheimer`s
26 Sep 2024 //
BUSINESSWIRE
Lundbeck Leaves US Trintellix To Takeda, Focuses On Rexulti
01 Aug 2024 //
FIERCE PHARMA
Otsuka And Lundbeck Present REXULTI® Data At AAIC 2024
31 Jul 2024 //
BUSINESSWIRE
Lundbeck To Present Migraine, Cluster Headache Data At American Headache Society
13 Jun 2024 //
BUSINESSWIRE
Otsuka, Lundbeck start ad push for long-acting bipolar drug
05 Jun 2024 //
FIERCE PHARMA
Lundbeck blames DTC blackout for slowdown in Rexulti growth
16 May 2024 //
FIERCE PHARMA
Rexulti the surprise winner in April`s TV drug ad spending list
07 May 2024 //
FIERCE PHARMA
Otsuka, Lundbeck sNDA for Brexpiprazole+Sertraline in PTSD
09 Apr 2024 //
PRESS RELEASE
Otsuka and Lundbeck Present New Data Analyses on the Efficacy of REXULTI
18 Mar 2024 //
BUSINESSWIRE
Lundbeck`s new CEO van Zyl talks long-term growth plan
23 Jan 2024 //
FIERCE PHARMA
Lundbeck encourages migraine patients to ‘Say Yep’ to its IV-infused med
19 Jan 2024 //
ENDPTS
Lundbeck, Otsuka dial down the drama for Rexulti agitation ad
13 Oct 2023 //
FIERCE PHARMA
Enforcement Report - Week of September 6, 2023
06 Sep 2023 //
FDA
AbbVie, Lundbeck ask FDA to revise draft guidance on migraine drugs
01 Aug 2023 //
ENDPTS
Otsuka, Lundbeck`s campaign spotlights agitation symptoms in Alzheimer’s disease
26 Jul 2023 //
ENDPTS
Lundbeck hires UCB neurology exec as new CEO
27 Jun 2023 //
FIERCE PHARMA
Lundbeck to Present New Clinical and Real-World VYEPTI® (eptinezumab-jjmr) Data
15 Jun 2023 //
BUSINESSWIRE
Otsuka & Lundbeck Announce US FDA Approval of (sNDA) for REXULTI®
10 May 2023 //
BUSINESSWIRE
Lundbeck out-licenses three candidates to Cambridge biotech
08 May 2023 //
ENDPTS
Neuro3 Therapeutics Acquires Exclusive Worldwide Rights to Devp KCNQ2 Lundbeck
08 May 2023 //
BIOSPACE
FDA Approves First Bi-Monthly Injectable for Schizophrenia, Bipolar 1
02 May 2023 //
CONTRACT PHARMA
Alloy to Empower Drug Discovery of Lundbeck’s Biologics for Brain Health
02 May 2023 //
BUSINESSWIRE
FDA Greenlights First Bi-Monthly Inje for Schizophrenia, Bipolar 1 Disorder
02 May 2023 //
BIOSPACE
FDA signs off on Otsuka and Lundbeck`s longer-acting Abilify
29 Apr 2023 //
FIERCE PHARMA
Otsuka, Lundbeck head into FDA panel with agency support
13 Apr 2023 //
FIERCE PHARMA
FDA backs Rexulti for first approval for agitation associated with Alzheimer’s dementia
12 Apr 2023 //
ENDPTS
Otsuka and Lundbeck Published Study Results Showing Aripiprazole 2-Month
04 Apr 2023 //
BUSINESSWIRE
Otsuka, Lundbeck eye Alzheimer`s indication in FDA adcomm
29 Mar 2023 //
ENDPTS
Takeda and Lundbeck change tactics on Trintellix depression campaign
23 Mar 2023 //
ENDPTS
FDA accepts one, delays another; Data, deals and dollars for slate of biotechs
09 Jan 2023 //
ENDPTS
Otsuka and Lundbeck Announce FDA Acceptance of sNDA for Brexpiprazole
07 Jan 2023 //
BUSINESSWIRE
Otsuka & Lundbeck Present Positive Data From Phase 3 Studies for Brexpiprazole
01 Dec 2022 //
BUSINESSWIRE
Lundbeck-partnered preclinical biotech nabs Series A from AstraZeneca
29 Nov 2022 //
ENDPTS
In new deal, AstraZeneca places small bet on `critical but challenging` target
28 Nov 2022 //
ENDPTS
Lundbeck`s Biologic Vyepti (Eptinezumab) Receives Approval in the U.S.
21 Oct 2022 //
FDA
Otsuka And Lundbeck Generate Exploratory Data In Major Depressive Disorder
03 Oct 2022 //
NEWSWISE
FDA accepts Otsuka filing for long-acting schizophrenia drug
14 Sep 2022 //
FIERCEPHARMA
Otsuka and H. Lundbeck Sue Viatris Over Abilify Maintena Again
06 Sep 2022 //
FDANEWS
Setback at Lundbeck: CGRP migraine drug Vyepti hits trial snag
19 Aug 2022 //
FIERCEPHARMA
Otsuka & Lundbeck shows reduced agitation treated with brexpiprazole
04 Aug 2022 //
PRESS RELEASE
Otsuka Pharma and Lundbeck present positive results showing reduced agitation
04 Aug 2022 //
BUSINESSWIRE
Otsuka Pharmaceutical and Lundbeck to Present PIII Data for Brexpiprazole
02 Aug 2022 //
BUSINESSWIRE
Lundbeck Gets A Much-Needed Win, But The Investment Case Is Still Not Clear-Cut
14 Jul 2022 //
SEEKING ALPHA
Lundbeck, Otsuka drug cut agitation in Alzheimer`s patients
28 Jun 2022 //
FIERCEPHARMA
EMA Commences Review of Aripiprazole 2-Month Long-Acting Injectable
17 Jun 2022 //
PRESS RELEASE
Results from the DELIVER study with Vyepti has been published
16 Jun 2022 //
CISION NEWS
Lundbeck to Present Data on VYEPTI at the Annual Meeting of AHS for Migraine
09 Jun 2022 //
BUSINESSWIRE
Lundbeck to Present New Data at AAN 2022
02 Apr 2022 //
BUSINESSWIRE
Sun Pharma enters licensing pact with Lundbeck to launch anti-depressant pill
30 Mar 2022 //
ECONOMIC TIMES
Lundbeck, Mental Health America tackle the other COVID crisis
24 Feb 2022 //
FIERCEPHARMA
Tracking mental health: Lundbeck partnership debuts US mapping dashboard tool
18 Feb 2022 //
ENDPTS
Lundbeck`s Vyepti (Eptinezumab) Receives Approval in Europe
15 Feb 2022 //
EMA
Otsuka, Lundbeck Announce FDA Approval of sNDA for REXULTI
06 Jan 2022 //
BUSINESSWIRE
Lundbeck appoints Dr. Rupert Sandbrink as Head of Clinical Development
21 Dec 2021 //
CISION
